TABLE 4.
Reclassification analysis from biomarkers related to pulmonary arterial hypertension in multivariable-adjusted models
| Biomarker added to the composite treatment and prognosis goals# | NRI (95% CI) | IDI (95% CI) | |
| Categorical | Continuous | ||
| ProANP | 0.3235 (0.1285–0.5185) (p=0.00115) | 0.6993 (−0.0045–1.403) (p=0.05149) | 0.1262 (−0.0343–0.2867) (p=0.1233) |
| hsTnT | 0.2571 (0.0921–0.4222) (p=0.00226) | 0.7683 (0.0726–1.464) (p=0.03042) | 0.1429 (−0.0496–0.3354) (p=0.1456) |
| GDF-15 | 0.1143 (−0.0395–0.2681) (p=0.1453) | 0.654 (−0.0524–1.36) (p=0.06959) | 0.0814 (−0.0829–0.2457) (p=0.3315) |
| sFlt-1 | −0.0286 (−0.0838–0.0266) (p=0.3103) | 0.3683 (−0.3557–1.092) (p=0.3187) | 6e−04 (−0.0054–0.0065) (p=0.8554) |
| PlGF | −0.0286 (−0.0838–0.0266) (p=0.3103) | 0.3048 (−0.3946–1.004) (p=0.393) | 0.0137 (−0.0083–0.0356) (p=0.2226) |
| ProANP+hsTnT | 0.2941 (0.1206–0.4676) (p=0.00089) | 0.817 (0.1254–1.509) (p=0.02059) | 0.1582 (−0.0338–0.3502) (p=0.1064) |
| ProANP+GDF-15 | 0.2647 (0.0769–0.4525) (p=0.00574) | 0.7582 (0.0601–1.456) (p=0.03327) | 0.1312 (−0.0393–0.3018) (p=0.1315) |
| hsTnT+GDF-15 | 0.2 (0.0265–0.3735) (p=0.02387) | 0.7111 (0.0098−1.412) (p=0.04688) | 0.1482 (−0.044–0.3403) (p=0.1307) |
| ProANP+sFlt-1 | 0.3529 (0.1552–0.5507) (p=0.00047) | 0.6405 (−0.0686–1.35) (p=0.07667) | 0.1264 (−0.0339–0.2867) (p=0.1222) |
| hsTnT+sFlt-1 | 0.2857 (0.0988–0.4726) (p=0.00274) | 0.8825 (0.1999−1.565) (p=0.01128) | 0.1474 (−0.0453–0.3401) (p=0.1338) |
| ProANP+PlGF | 0.2941 (0.1024–0.4858) (p=0.00264) | 0.4641 (−0.2574–1.185) (p=0.2074) | 0.1545 (−0.0132–0.3221) (p=0.07091) |
| hsTnT+PlGF | 0.2857 (0.1164–0.455) (p=0.00094) | 0.4825 (−0.2359–1.201) (p=0.188) | 0.1588 (−0.0352–0.3529) (p=0.1086) |
Risk categories: low, 0–2%; intermediate, 2–15%; high, ⩾15%. NRI: net reclassification index; IDI: integrated discrimination index; proANP: pro-atrial natriuretic peptide; hsTnT: high-sensitivity troponin T; GDF-15: growth differentiation factor 15; sFlt-1: soluble fms-like tyrosine kinase 1; PlGF: placental growth factor. #: World Health Organization functional class, 6-min walk test, tricuspid annular plane systolic excursion, peak oxygen uptake, N-terminal pro-brain natriuretic peptide and cardiac index. Bold indicates statistical significance.